{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:47:08Z","timestamp":1794952028024,"version":"4.9.1"},"reference-count":30,"publisher":"BMJ","issue":"9","funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2016,2,14]]},"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      The objective of this study was to assess the efficacy, safety and tolerability of vonoprazan, a novel potassium-competitive acid blocker, as a component of\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      eradication therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>\n                      A randomised, double-blind, multicentre, parallel-group study was conducted to verify the non-inferiority of vonoprazan 20\u2005mg to lansoprazole 30\u2005mg as part of first-line triple therapy (with amoxicillin 750\u2005mg and clarithromycin 200 or 400\u2005mg) in\n                      <jats:italic>H pylori-<\/jats:italic>\n                      positive patients with gastric or duodenal ulcer history. The first 50 patients failing first-line therapy with good compliance also received second-line vonoprazan-based triple therapy (with amoxicillin 750\u2005mg and metronidazole 250\u2005mg) as an open-label treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 650 subjects randomly allocated to either first-line triple therapy, 641 subjects completed first-line therapy and 50 subjects completed second-line therapy. The first-line eradication rate (primary end point) was 92.6% (95% CI 89.2% to 95.2%) with vonoprazan versus 75.9% (95% CI 70.9% to 80.5%) with lansoprazole, with the difference being 16.7% (95% CI 11.2% to 22.1%) in favour of vonoprazan, thus confirming the non-inferiority of vonoprazan (p&lt;0.0001). The second-line eradication rate (secondary end point) was also high (98.0%; 95% CI 89.4% to 99.9%) in those who received second-line therapy (n=50). Both first-line triple therapies were well tolerated with no notable differences. Second-line triple therapy was also well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Vonoprazan is effective as part of first-line triple therapy and as part of second-line triple therapy in\n                      <jats:italic>H pylori-<\/jats:italic>\n                      positive patients with a history of gastric or duodenal ulcer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NCT01505127.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2015-311304","type":"journal-article","created":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T18:18:09Z","timestamp":1460571489000},"page":"1439-1446","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":428,"title":["Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for\n                    <i>Helicobacter pylori<\/i>\n                    eradication: a phase III, randomised, double-blind study"],"prefix":"10.1136","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct01505127","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kazunari","family":"Murakami","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuichi","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Ltd., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madoka","family":"Shiino","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Ltd., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Funao","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Ltd., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Ltd., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Asaka","sequence":"additional","affiliation":[{"name":"Health Sciences University of Hokkaido, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,3,2]]},"reference":[{"key":"2025120518343099000_65.9.1439.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020542"},{"key":"2025120518343099000_65.9.1439.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1001110"},{"key":"2025120518343099000_65.9.1439.3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27965"},{"key":"2025120518343099000_65.9.1439.4","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32978"},{"key":"2025120518343099000_65.9.1439.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04887.x"},{"key":"2025120518343099000_65.9.1439.6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302084"},{"key":"2025120518343099000_65.9.1439.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01393.x"},{"key":"2025120518343099000_65.9.1439.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2009.00738.x"},{"key":"2025120518343099000_65.9.1439.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f4587"},{"key":"2025120518343099000_65.9.1439.10","doi-asserted-by":"publisher","DOI":"10.1038\/ncpgasthep1138"},{"key":"2025120518343099000_65.9.1439.11","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00740-07"},{"key":"2025120518343099000_65.9.1439.12","first-page":"98","article-title":"The current prevalence of drug-resistant Helicobacter pylori in Japan\u2014a summary of 2006 surveillance of resistant bacteria and a 5-year summary","volume":"10","author":"Kobayashi","year":"2009","journal-title":"J Japan Soc Helicobacter Res"},{"key":"2025120518343099000_65.9.1439.13","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12796"},{"key":"2025120518343099000_65.9.1439.14","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.185314"},{"key":"2025120518343099000_65.9.1439.15","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.170274"},{"key":"2025120518343099000_65.9.1439.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.02.009"},{"key":"2025120518343099000_65.9.1439.17","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.179556"},{"key":"2025120518343099000_65.9.1439.18","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.18"},{"key":"2025120518343099000_65.9.1439.19","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13121"},{"key":"2025120518343099000_65.9.1439.20","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13331"},{"key":"2025120518343099000_65.9.1439.21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.2001.00037.x"},{"key":"2025120518343099000_65.9.1439.22","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.30.2238"},{"key":"2025120518343099000_65.9.1439.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00456-3"},{"key":"2025120518343099000_65.9.1439.24","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780091208"},{"key":"2025120518343099000_65.9.1439.25","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.200610373"},{"key":"2025120518343099000_65.9.1439.26","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. CLSI document M100-S17 [ISBN 1-56238-625-5]."},{"key":"2025120518343099000_65.9.1439.27","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.51.8510"},{"key":"2025120518343099000_65.9.1439.28","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.1.5"},{"key":"2025120518343099000_65.9.1439.29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.2078"},{"key":"2025120518343099000_65.9.1439.30","unstructured":"IARC Helicobacter pylori Working Group. Helicobacter pylori eradication as a strategy for preventing gastric cancer. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 8), 2014. http:\/\/www.iarc.fr\/en\/publications\/pdfs-online\/wrk\/wrk8\/index.php (accessed 19 Oct 2015)."}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2015-311304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T02:34:37Z","timestamp":1764988477000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2015-311304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,2]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,8,9]]},"published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1136\/gutjnl-2015-311304"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2015-311304","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,2]]}}}